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Abstract

Pulmonary infections are incredibly dangerous for humans, with the risks increased for
those that are immunocompromised. The development of drug-resistant fungal strains has
created a critical issue with pulmonary infections in public health. Specifically, pulmonary
aspergillosis caused by fungi Aspergillus is the focus of this study. Currently, for aspergillosis
treatment, antifungals are in intravenous and oral forms. Antifungal drugs are mostly
hydrophobic and have little water solubility. Therefore, low water solubility restricts high
concentrations of the antifungal drug to be delivered to the lung and has low circulatory times.
Here, we use mesoporous silica nanoparticles (MSNs) as nanocarriers to deliver antifungal drug,
Amphotericin B (AmpB). The nanocarrier allows for the low water soluble AmpB to be
delivered in higher dosage to Aspergillus. MSNs were synthesized using a template method. The
AmpB loading and release was observed using UV-visible spectroscopy, and thermogravimetric
analysis was used for characterization and nanoassembly. In order to test the efficacy of the
released AmpB, its antifungal activity was observed against Aspergillus flavus (A. flavus).
Colorimetric antifungal assay and colony counting was performed to determine antifungal
efficacy.
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Introduction

Aspergillus flavus, a soil fungus, is in the Aspergillus genus of fungi, and it is commonly
found in household mold and molds infecting agricultural products. The Aspergillus genus
1

contains nearly 200 different species, with less than 50 of those causing infections in humans.
Other fungi in the genus include A. fumigatus, A. terreus, and A. niger, which all cause infections
in humans. While A. fumigatus is the leading fungi in the genus in relation to invasive
aspergillosis, A. flavus leads in superficial infection and is the second most common fungi to
cause invasive aspergillosis. A. flavus also causes keratitis and chronic granulomatous sinusitis in
humans, where the breakouts of the fungi are generally attributed to one strain or a few strains
that are closely related. There are many biochemical and morphological characteristics of A.
2

flavus that can make identifying the species difficult, as there is a substantial amount of overlap
between species. Much of the research that has been completed on the genus has focused on A.
fumigatus, due to its prevalence in the environment and in infecting humans, so more research on
the characteristics of A. flavus is necessary.
Aspergillus flavus is prevalent in soil, both indoor and outdoor air, and water, which
explains its effectiveness in infecting humans. The fungi is capable of surviving harsh conditions
2

in different climates, so it is often able to survive when other species would be unable to. A.
flavus exists as a saprophyte in soil, and it recycles organic matter that has died and decayed,
which makes it an important part of any ecosystem. A. flavus is often found in the air of warmer
climates, and it has been specifically found in larger quantities in the air of tropical regions. It
3

has also been found in hospitals and other buildings following construction, which has led to
major risks for infection.
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Pulmonary aspergillosis is a disease that can be attributed to an infection in the lungs
caused by Aspergillus, most notably A. flavus and A. fumigatus. The infection is caused by
inhalation of the fungi’s spores from the conidia, and it can range in severity. Pulmonary
infections are incredibly dangerous for humans, with the risks increased for those that are
immunocompromised. Those that are immunocompromised or have preexisting conditions are
4

most greatly affected, as their bodies are unable to fight off the infection as others would. In
certain cases, the infection can spread to other vital organs and parts of the body, causing
possible organ damage or death. Aspergillosis can cause a variety of symptoms, including cough,
fever, chest pain, difficulty breathing, and shortness of breath. Because these symptoms are
synonymous with many other diseases and infections, it is often difficult to diagnose
aspergillosis.
Treatment for aspergillosis ranges, as it is dependent on the patient, strain of fungus, and
severity of infection. The development of drug-resistant fungal strains has created a critical issue
with pulmonary infections in public health. Currently, for aspergillosis treatment, antifungals are
in intravenous and oral forms. Antifungal drugs are mostly hydrophobic and have little water
5

solubility. Therefore, low water solubility restricts high concentrations of the antifungal drug to
be delivered to the lung and has low circulatory times.
Amphotericin B (AmpB) is an antifungal drug which is commonly used for treatment of
antifungal-resistant fungal infections. Research has shown that Amphotericin B provides
sufficient drug solubilization and drug stability in treatment of fungal infections. AmpB is in the
6

polyene antibiotics class, and it is taken from cultures of S. nodosus. Because of its mostly
hydrophobic nature, the drug forms aggregates in concentrations of water at 2x10 . The drug is
-7 7

an incredibly efficient antimycotic agent, and it is used for the treatment of aspergillosis.
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However, the drug has several dose-dependent side effects, with nephrotoxicity being notable. In
8

order to reduce these side effects, researchers are studying different formulas and methods of
treatment using Amphotericin B.

Figure 1: Skeletal structure of Amphotericin B.
In order to lessen the potential side effects of Amphotericin B and to create a more
targeted approach of treatment, nanoparticles are used in this project. Nanotechnology allows for
the drug to be delivered directly to the source of infection, which limits the amount of drug
present in other parts of the body. This lessens the amount of potential side effects and delivers a
9

higher dosage of drug to the infected area, which then allows for the infection to be treated more
easily and efficiently. Along with this, nanoparticles are used as drug carriers when treating drug
resistance in pathogens, as they are able to be directed to specific types of cells rather than
causing negative effects to all surrounding cells. Mesoporous silica nanoparticles (MSNs)
contain pores and are hydrophilic, which allow for the drug, AmpB, to be carried and compatible
with the carrier.
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The purpose of this project is to provide safer and more efficient detection and treatment
options for those infected by Aspergillus through the use of drug-loaded, mesoporous silica
nanoparticles. The AmpB loading and release will be observed using UV-visible spectroscopy
and thermogravimetric analysis. AmpB is active within the UV-Vis range, which allows for it to
be studied. In order to test the efficacy of the released AmpB, its antifungal activity will be
10

observed against Aspergillus flavus. Colorimetric antifungal assay and colony counting will be
performed to determine antifungal efficacy.
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Materials and Methods
The following items were purchased from Sigma Aldrich (Missouri, USA):
hexadecyltrimethylammonium bromide (CTAB), tetraethyl orthosilicate (TEOS, 98%), sodium
hydroxide solution (28.0-30.0%), 3-aminopropyltriethoxysilane (APTES), phosphate buffered
saline (PBS) tablets. Hydrochloric acid (36.5-38.0%), methanol, potato dextrose agar (PDA),
Tween®-20, Tween®-80, dimethyl sulfoxide (DMSO), HPLC-grade acetonitrile (ACN), HPLCgrade water with 0.1% trifluoroacetic acid (TFA), and Corning TM RPMI 1640 with Lglutamine, without sodium bicarbonate were purchased from ThermoFisher Scientific
(Massachusetts, USA). The following items were purchased from Alfa Aesar (Massachusetts,
USA): itraconazole (98%) and 3-(N-morpholino)propanesulfonic acid) (MOPS), and sodium
hydroxide was purchased from LabChem (Pennsylvania, USA). Aspergillus flavus var. flavus
(ATCC ® 22546 TM ) was obtained from American Type Culture Collection (Virginia, USA).
All work with fungi was completed under laminar flow, with sterile media, glassware,
and disposables. The glassware and media used was sterilized in a Bioclave 16 L Benchtop
Autoclave (Ward’s Science, New York, USA). The fungal samples were incubated in a C-25KC
Classic Incubator (New Brunswick Scientific, New Jersey, USA). The absorbance measurements
were obtained using a Spectramax M2 plate reader (Molecular Devices Ltd., California, USA),
and all transmission electron microscopy (TEM) images were found on a FEI Tecnai G2 Osiris
S/TEM (FEI Company, Oregon, USA). The hydrodynamic size and zeta potential of the
nanoparticles was measured with a Malvern Nano-ZS Zetasizer (Malvern Panalytical Inc.,
Worcestershire, UK). Thermogravimetric analysis (TGA) was performed with a Discovery Q500
TGA (TA Instruments, Delaware, USA), and all high performance liquid chromatography
(HPLC) was obtained with a Hitachi Primaide HPLC system (Hitachi Ltd., Tokyo, Japan)
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equipped with a pump (1110), an autosampler (1210), a column oven (1310), and a diode array
detector (1430).
Synthesis of MSNs
Cetyl trimethyl ammonium bromide (CTAB) solution was created by dissolving 204 mg,
4 mmol of CTAB in 140 mL of water. A solution of 1688 µL, 7.6 mmol TEOS, and 1688 µL
ammonium hydroxide, 25% v/v% was added dropwise to the CTAB solution. The solution was
then stirred at 400 rpm at room temperature overnight. The next day, the MSNs were centrifuged
at 7,830 rpm for ten minutes. The MSNs were then redispersed in water, centrifuged, and
redispersed in 50 mL of ethanol that contained 200 µL conc. HCl. This removed the CTAB
surfactant, and the mixture was then stirred at 60 ℃ overnight. The MSNs were then purified by
centrifugation at 7,830 rpm for ten minutes three times, and finally dispersed in water. Figure 2
shows the template method used for synthesizing the MSNs.
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Figure 2: Cetyl trimethyl ammonium bromide (CTAB) solution and tetraethyl orthosilicate
(TEOS) combine to form MSNs, which are purified through centrifugation. This was created
using BioRender.com.
Encapsulation of AmpB in MSNs
In order to load the MSNs with AmpB, 1 mg/mL of AmpB in DMSO was combined with
10 mg of the dried MSNs. This mixture was then left to stir overnight at 400 rpm. It was
centrifuged at 12,000 rpm for 10 minutes, in order to obtain the AmpB@MSNs. In order to
remove the excess drugs, the AmpB-loaded MSNs were washed three times with water. Figure 3
shows the liposome encapsulated, AmpB loaded MSNs being delivered to the Aspergillus.
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Figure 3: The MSNs are loaded with the drug, AmpB, to be delivered to the Aspergillus fungi.
This was created using BioEender.com.
Characterization of AmpB@MSNs
The size and surface charge of the nanoparticles was determined through dynamic light
scattering (DLS). Transmission electron microscopy was used to capture images of the
nanoparticles with an accelerating voltage of 200 kV. The samples were prepared with 200 mesh
carbon thin-film-coated Cu grids that were drop-casted with a diluted solution of the
nanoparticle, which was then vacuum dried overnight.
Determining Release of AmpB
The AmpB release from MSN was observed at 396 nm using UV-vis spectroscopy, with
size and zeta potential being found. To obtain the supernatant, the sample was diluted 20-fold in
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methanol in order to correspond the sample to a concentration that was within the linear range.
The absorbance measurements were found on a multimode plate reader that was equipped with a
UV-Vis detector as wavelength 261 nm, and the concentration was found based on the
calibration curve.
Released AmpB Efficacy on A. flavus
A tetrazolium-based MTT assay was used as a colorimetric assay, and a colony counting
assay was used to determine the released AmpB efficacy.
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Results

AmpB drug loaded MSNs (AmpB@MSNs) were ~ 280 nm in diameter (see Table 1).
The surface charge of the nanocarrier was - 19 mV. AmpB has a zeta potential of -19 mV, and
the MSN has a zeta potential of -23 mV. Successful loading of AmpB in MSN can be visualized
through the reduction of zeta potential from -23 mV in MSN to -19 mV in AmpB@MSN.
Size and Surface Charge Characterization of AmpB@MSNs
Sample

Size (Volume, nm) Polydispersity Index

Average Zeta Potential

AmpB

-19.47 ± 0.47

MSN

-23.1 ± 0.781

AmpB @ MSN

277.4 ± 16.42

0.614 ± 0.051

-19.0 ± 0.2

Table 1: The characterization of AmpB@MSNs in relation to size and surface charge.
AmpB loading was calculated to be 625 µg in 1 mg of MSN (see Table 2). The
encapsulation efficiency and drug loading capacity was 63% and 69%. Although high loading of
the drug was seen, AmpB release was remarkably low (<5%) (see Figure 3).
Drug Loading - AmpB@MSN

Encapsulation Efficiency

Drug Loading Capacity

AmpB per mg MSN

62.5%

68.7%

625 µg

Table 2: The encapsulation efficiency and drug loading capacity of AmpB@MSN.
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Figure 3: The drug encapsulated nanoparticle released AmpB to the conidia across the timespan
of 50 hours.
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Discussion

This project studied the use of drug-loaded, mesoporous silica nanoparticles in the
treatment and detection of A. flavus. Treatment for aspergillosis was tested using the antifungal
drug Amphotericin B, which was loaded into the mesoporous silica nanoparticles. The AmpB
loading and release was observed using UV-visible spectroscopy, as AmpB is active within the
UV-Vis range. The efficacy of the released AmpB was tested with its antifungal activity
10

observed against Aspergillus flavus, and colorimetric antifungal assay and colony counting were
performed to determine antifungal efficacy.
Previous literature found that Amphotericin B worked well as a treatment for antifungalresistant fungal infections, and forms of Aspergillus have evolved to be antifungal-resistant.
AmpB has been found to treat fungal infections adequately, with sufficient drug solubilization
and drug stability. As Amphotericin B is mostly hydrophobic, it works well in the hydrophilic
6

mesoporous silica nanoparticles. Since the drug has various side effects, this form of treatment,
with lower doses able to be used, has the potential to be life-saving. With many of the side
effects being dose-dependent, the ability to lower the dosage with a targeted drug delivery
approach will provide less severe side effects.
AmpB drug loaded MSNs (AmpB@MSNs) were ~ 280 nm in diameter, and the zeta
potential for AmpB was given as -19.47 ± 0.47, and the zeta potential for MSN was given as 23.1 ± 0.781. AmpB in MSN can be seen through the reduction of zeta potential from -23 mV in
MSN to -19 mV in AmpB@MSN, which indicates that the drug was loaded successfully. The
encapsulation efficiency and drug loading capacity was 63% and 69%, but despite high loading
of the drug being seen, AmpB release was remarkably low (<5%). The released AmpB did not
have sufficient antifungal activity to afford minimum inhibitory effect on A. flavus compared to
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the free drug AmpB, which means that the drug did not release properly. Since the drug was
successfully loaded into the MSN, there was an error in the release of the drug. This could have
been caused by the drug being unable to release through the pores of the nanoparticle. With
further research, the drug itself could be replaced for treatment in order to test that the
nanoparticle is not the cause of the error.
Nanotechnology is being studied in relation to providing a targeted drug delivery
approach and in detection and diagnosis of aspergillosis. Since the nanoparticles used allow for
the drug to be delivered directly to the source of infection and specific cells, the quantity of drugs
affecting other parts of the body are less likely to experience effects of the drug. This also allows
9

for a higher dosage of the drug to be delivered to the infected area, which will cause the area to
be treated more quickly.
Lectins, a class of carbohydrate-binding proteins, can be used to create a nanoparticle that
detects Aspergillus. Aspergillus conidia produces DHN-melanin, which is a component of the
conidial cell wall surface that gives the fungi their color, which can range from yellow to black.
The lectin to be used in this project is MelLec, which binds to DHN-melanin. This lectin can be
attached to magnetic nanoparticles, otherwise referred to as MNPs, and the mechanism would be
used to test for Aspergillus using the precipitate of the MNPs following detection of the
aspergillosis.
The increased risks for immunocompromised individuals with aspergillosis indicates that
more research is needed in regards to the treatment and diagnosis of the disease. This should
include different methods of treatment as well as different antifungal drugs. With
nanotechnology being a newer field and more research consistently being conducted, the many
ways that nanoparticles can detect and treat diseases will continue to be a focus.
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